5:20 PM
 | 
Nov 27, 2018
 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim CEO while a permanent successor is sought.

Prior to Abeona, Thiel served as CCO of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) until his departure in 2017, one of several from that company amid an investigation into Alexion’s sales practices for Soliris eculizumab (see “Alexion Shuffles Management Again”).

INKEF Capital hired Roel Bulthuis as managing director to co-manage the firm’s €500 million ($568.6 million) venture fund. Bulthuis was SVP and managing director at M Ventures. The firm, which focuses on technology and healthcare investments, has invested in hematology company ProFibrix B.V., which The Medicines Co. (NASDAQ:MDCO) acquired in 2013,...

Read the full 636 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >